CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece.
Gianni GhettiLorenzo PradelliGiannis PapageorgiouGeorge KarpouzosYelda ArikanPublished in: ClinicoEconomics and outcomes research : CEOR (2023)
The analysis demonstrated that for type 2 diabetes patients, empagliflozin is a cost-effective treatment option versus branded sitagliptin in Greece.